Neurological
Refine Search
Biotechnology
Alzheimer’s Leqembi, Launched , China 28 June 2024
Biotechnology
US RNA specialist Wave Life Sciences has presented positive results from its Phase Ib/IIa SELECT-HD trial of WVE-003, which is being developed as a potential disease modifying therapeutic for Huntington’s disease (HD). 26 June 2024
Pharmaceutical
Braeburn has published a post hoc analysis of data from a Phase III trial of Brixadi (buprenorphine) in the Journal of the American Medical Association (JAMA). 26 June 2024
Biotechnology
Swiss pharma giant Roche has announced that the European Commission has granted marketing authorization for Ocrevus (ocrelizumab) subcutaneous (SC) to treat relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). 25 June 2024
Pharmaceutical
Vanda Pharma rejects unsolicited takeover bids 20 June 2024
Pharmaceutical
Bensheim-based medical cannabis specialist Avextra has announced a strategic partnership with fellow German firm SynQube. 20 June 2024
Pharmaceutical
CNS disorder specialist Intra-Cellular Therapies has announced positive topline results from Study 502, evaluating its depression candidate lumateperone. 19 June 2024
Biotechnology
Ascidian Therapeutics inks collaboration with Roche 19 June 2024
Biotechnology
US biotech Arvinas has promoted Ian Taylor to president of R&D. Angela Cacace will take over from Dr Taylor in his current role of chief scientific officer. 18 June 2024
Pharmaceutical
Marinus Pharmaceuticals has announced topline results showing partial success in the Phase III RAISE trial. 18 June 2024
Pharmaceutical
New data on Radicava for people with ALS presented at ENCALS 18 June 2024
Pharmaceutical
Takeda’s epilepsy drug soticlestat misses Phase III endpoints 17 June 2024
Biotechnology
Avidity Biosciences, a biopharmaceutical company specializing in RNA therapeutics, has announced a public share offering, with the goal of raising $400 million. 14 June 2024
Biotechnology
The market for amyotrophic lateral sclerosis (ALS) across mature markets could reach $1.3 billion by 2029, up from $317 million in 2019, according to GlobalData 13 June 2024
Pharmaceutical
Alzheon, a clinical-stage biopharma company, has secured $100 million in a series E funding round led by Alerce Medical Technology Partners. 13 June 2024
Pharmaceutical
NICE’s decision to not re-appraise Spravato “gravely concerning,” says J&J 13 June 2024
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze